Company intelligence
Abionic
Lab-quality results within minutes, at the point-of-care!
About Abionic
The winner of multiple industry awards, including "Swiss MedTech of the year" in 2023, Abionic is a Swiss MedTech company spun-out of EPFL in 2010 on a vision nanofluidics could transform diagnostics. Our flagship abioSCOPE®, a near-patient rapid diagnostic platform, delivers lab-quality results from a drop of blood within minutes, providing valuable clinical insights and actionable information at the point-of-care.
Verified activity
Signals from Abionic
6 published signals
Research & Knowledge
Abionic developed and tested the PSP sentinel assay for detecting subclinical infections in critical care.
Reported by Abionic
Presence & Recognition
Abionic is hosting a webinar on tracking Pancreatic Stone Protein (PSP) to detect subclinical infectious signals in severe trauma and burn cases during Sepsis Awareness Month
Reported by Abionic
Presence & Recognition
Abionic CTO Iwan Märki is briefing attendees at the NATO Medical Innovation Workshop in Budapest on deploying the sentinel biomarker PSP in high-stakes military care.
Reported by Abionic
Presence & Recognition
Abionic will meet the CEO during the upcoming LSX London Investment Showcase.
Reported by Abionic
Products & Services
Abionic established its rapid bedside Dx platform in emergency and acute care and is bringing its dual-use potential to defense and austere care environments.
Reported by Patrick Pestalozzi
Capital & Finance
Abionic is raising capital to deploy rapid bedside diagnostics across emergency and acute care to reveal subclinical infections within minutes.
Reported by Patrick Pestalozzi